arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Vera Therapeutics, Inc.

VERA
$32.86 ▲ +0.84 (+2.62%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Weak
Neutral
auto_awesome

Analytical Summary

Vera Therapeutics, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.3B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -17.2%
FCF / Share $-1.49
Trailing P/E
Price / Book 4.7x
FCF Yield
Debt / Equity 0.15
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-121.03M
↓ -134.1%
FCF / Share Free cash flow per share
$-1.49
↓ -73.8%
Long-Term Debt Long-term obligations
$75.03M
— +0.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Financial Health
49
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters